Main Menu

It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.

Summary:

The National Center for Complimentary and Integrative Health (NCCIH) seeks licensees and/or commercial partners to develop topical formulations of margaric acid to treat allodynia, neuropathy, and pain caused by chronic inflammation.  

The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects.

The technology outlined in the document is focused on the discovery of novel biomarkers for Onchocerciasis, a parasitic disease also known as river blindness, which is transmitted by blackfly vectors. The document describes the identification of the first Onchocerca volvulus-encoded molecules that are adult-specific and can be used as markers for macrofilaricidal activity, which is the ability to kill adult worms.